Incyte reported preliminary results from a study targeting calreticulin (CALR) mutations in myelofibrosis, showing meaningful spleen response rates and symptom improvement in advanced disease. The data, presented at ASH, describe a new mechanism distinct from JAK inhibition and aim to broaden treatment options. Executives framed the program as necessary as Jakafi faces upcoming patent cliffs; the results could support development of a differentiated asset in myelofibrosis. Investigators emphasized the data are preliminary and require confirmation in larger trials.